Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$12.6MCash on Hand
6.2mo Cash Runway
Follow DARE by emailGet an email when DARE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DARE, unsubscribe in one click. Privacy
📣 What DARE Says Is Next
in 2027 · “Topline results are expected in 2027. ○ Received a funding award notice for a second $1.0 million tranche from the National Institute of Allergy and Infectious Disease (NIAID), a division of the NIH, bringing the total funding award for the DARE-HPV program across the project period that began in December 2024 to $2.0 million.”
Company press release, Aug 13, 2026 · SEC filing
in 2026 · “Daré currently anticipates enrollment to complete in 2026, which would put a 2027 topline data readout within reach and advance the potential premarket approval (PMA) pathway for what has the potential to be the first non-implanted, non-hormonal monthly contraceptive option on the market.”
Company press release, Mar 26, 2026 · SEC filing
early 2027 · “Daré is targeting to have DARE to RECLAIM available for prescription fulfillment in the U.S. in early 2027 through a 503B-registered outsourcing facility and a dispensing pharmacy, while simultaneously pursuing activities to support an investigational new drug (IND) application filing for a pivotal Phase 3 clinical study of DARE-HRT1, consistent with Daré’s dual-path strategy.”
Company press release, Mar 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 6, 2026 ·
Shareholder vote Daré Bioscience is holding a virtual special meeting on November 10, 2026 for stockholders to approve future issuance of common stock upon exercise of outstanding warrants, per Nasdaq rules, and to approve a possible adjournment to solicit more proxies. Form DEF 14A · SEC filing
Oct 2, 2026 ·
Listing Received a Nasdaq letter on September 28, 2026 saying the stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until March 29, 2027 to regain compliance, with a possible additional 180-day period. Form 8-K · SEC filing
Oct 1, 2026 ·
Daré Bioscience furnished a corporate presentation dated October 1, 2026 as Exhibit 99.1, for use in investor meetings beginning that day. The filing contains no new financial or clinical figures. Form 8-K · SEC filing · Press release
Sep 11, 2026 ·
Shareholder vote The board approved an amendment to the bylaws, effective immediately, lowering the stockholder meeting quorum from a majority to one-third of the voting power entitled to vote at the meeting. Form 8-K · SEC filing
Sep 9, 2026 ·
Daré Bioscience furnished a corporate presentation dated September 9, 2026, for use in meetings with securities market participants beginning that day. The filing contains no new financial results, trial data or deal terms. Form 8-K · SEC filing · Press release
Sep 4, 2026 ·
Financing Registers resale of up to 8,934,345 shares of common stock by selling stockholders, mainly shares issuable on exercise of Series A and Series B common warrants from a private placement, plus placement agent warrant shares. The company receives no proceeds from resales. Form 424B3 · SEC filing
Aug 26, 2026 ·
Financing Daré Bioscience filed a preliminary resale prospectus covering up to 8,934,345 shares of common stock issuable upon exercise of common warrants and placement agent warrants from a prior private placement. The company will not receive proceeds from resales. Last reported price was $0.80 per share on August 24, 2026. Form S-1 · SEC filing
Aug 17, 2026 ·
Financing Dare Bioscience is offering 4,085,687 shares of common stock and 293,894 pre-funded warrants at $1.37 per share, with concurrent private placement warrants and no minimum offering. Ladenburg Thalmann is placement agent, receiving 7.0% of gross proceeds. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
DARE holds $12.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.1M/quarter from operations,
an estimated runway of 6.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:67 · High
Cash runway 6 months +30
ATM program on file since May 2024 +15
Shelf registration (S-3, Mar 2024) +10
Going-concern doubt in the latest 10-Q +15Based on the Company’s current analysis of the conditions described above, there is substantial doubt about the Company's ability to continue as a going concern 7 within the 12 month period from the issuance date of the accompanying condensed consolidated financial statements given that the timing and amount of…10-Q, Aug 2026
Share count +13% in a year +7
Raised after last reported balance sheet (Aug 2026) -10
Recent financing filings on SEC EDGAR:
Aug 17, 2026 · Registered direct / best-efforts offering · 424B5
Share count 15,289,502 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full DARE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DARE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.